Long-acting beta2 agonists.
Two applications claim very closely related arylsulfonamide beta(2)-agonists. The basic generic claim is the same in both cases with subsidiary claims covering different permutations of the same Markush structure. The claimed compounds are potent beta(2)-agonists whose structures suggest that they would have a long duration of action. These applications represent part of what is now a significant chemical programme at Pfizer.